rxstat › Shortages › Lamivudine
Lamivudine shortage status
Partial shortage
Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Lamivudine products are in shortage in Canada (1 of 6 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Jul 3, 2026.
In shortage since
Mar 31, 2026
Est. full return
Jul 3, 2026
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.
Reports by product
Active shortageAPO-LAMIVUDINE HBV
100MG · TABLET · APOTEX INC
DIN 02393239 · since Mar 31, 2026, est. end Jul 3, 2026 · Disruption of the manufacture of the drug.
Resolved3TC
10MG · SOLUTION · VIIV HEALTHCARE ULC
DIN 02192691 · ended Feb 21, 2025 · Disruption of the manufacture of the drug.
DiscontinuedHEPTOVIR
100MG · TABLET · GLAXOSMITHKLINE INC
DIN 02239193
DiscontinuedHEPTOVIR
5MG · SOLUTION · GLAXOSMITHKLINE INC
DIN 02239194
ResolvedAPO-LAMIVUDINE HBV
100MG · TABLET · APOTEX INC
DIN 02393239 · ended Jun 25, 2021 · Disruption of the manufacture of the drug.
ResolvedAPO-LAMIVUDINE
300MG · TABLET · APOTEX INC
DIN 02369060 · ended Jun 25, 2021 · Disruption of the manufacture of the drug.
ResolvedAPO-LAMIVUDINE HBV
100MG · TABLET · APOTEX INC
DIN 02393239 · ended Feb 21, 2020 · Disruption of the manufacture of the drug.
DiscontinuedAPO-LAMIVUDINE HBV
100MG · TABLET · APOTEX INC
DIN 02393239
DiscontinuedAPO-LAMIVUDINE
150MG · TABLET · APOTEX INC
DIN 02369052
DiscontinuedAPO-LAMIVUDINE
300MG · TABLET · APOTEX INC
DIN 02369060
ResolvedHEPTOVIR
5MG · SOLUTION · GLAXOSMITHKLINE INC
DIN 02239194 · ended Sep 12, 2017 · Demand increase for the drug.
ResolvedAPO-LAMIVUDINE
300MG · TABLET · APOTEX INC
DIN 02369060 · ended Aug 30, 2017 · Disruption of the manufacture of the drug.
Showing 12 of 13 reports. All reports are on file with Health Canada.
What's happening
Lamivudine is currently affected by an active shortage report filed with Health Canada by APOTEX INC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Lamivudine is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AF).
Recent changes
Common questions
When will Lamivudine be back in stock in Canada?
The latest manufacturer estimate is Jul 3, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Lamivudine in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Guides: what to do when your medication is in shortage · how to read shortage reports
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.